(Press-News.org) New Rochelle, NY, May 29, 2013—A novel, targeted approach to chemotherapy that makes ovarian cancer cells more susceptible to the cytotoxic effects of an antitumor drug may offer a safer, more effective treatment option for this often deadly form of cancer. The research and results are published in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers (http://www.liebertpub.com). The article is available on the Nucleic Acid Therapeutics website (http://www.liebertpub.com/nat).
Ovarian cancer is usually diagnosed at an advanced stage of disease, and although most patients initially respond to conventional chemotherapeutic agents, the cancer typically recurs and the overall survival rate is poor. Furthermore, current chemotherapeutics for ovarian cancer are nonspecific and generally toxic causing debilitating side effects. More effective and specific agents are needed that target ovarian cancer cells and inhibit their ability to reproduce.
Sibaji Sarkar and Douglas Faller, Boston University School of Medicine (Boston, MA), successfully advanced their research to develop anti-tumor drugs comprised of nucleic acids, the building blocks of DNA. They had previously shown that so-called "GT-oligos" (which target and bind to nucleic acid sequences present in regions found at the ends of chromosomes, called telomeres) can trigger cell death in certain types of cancer cells, including ovarian, pancreatic, and prostate cancer. However not all cancer cells in these and other tumor types are susceptible to the effects of GT-oligos.
In the current study the authors take this work a step further and demonstrate a novel method to sensitive resistant ovarian cancer cells to this targeted chemotherapeutic approach. They describe the details of this strategy and the potential to apply this technique more broadly to treat other types of epithelial cancers in the article " Telomere-Homologous G-rich Oligonucleotides Sensitize Human Ovarian Cancer Cells to TRAIL-Induced Growth Inhibition and Apoptosis." (http://online.liebertpub.com/doi/full/10.1089/nat.2012.0401)
"The devastating mortality rate from ovarian cancer has not changed since the 'War on Cancer" was declared in 1971," says Executive Editor Fintan Steele, PhD, SomaLogic, Inc., Boulder, CO. "We need to improve both early diagnosis and find novel treatments. The work by Sarker and Faller provides a new and promising approach for treatment of this particularly difficult form of cancer."
INFORMATION:
Nucleic Acid Therapeutics is under the editorial leadership of Co-Editors-in-Chief Bruce A. Sullenger, PhD, Duke Translational Research Institute, Duke University Medical Center, Durham, NC, and C.A. Stein, MD, PhD, City of Hope National Medical Center, Duarte, CA; and Executive Editor Fintan Steele, PhD (SomaLogic, Boulder, CO).
About the Journal
Nucleic Acid Therapeutics is an authoritative, peer-reviewed journal published bimonthly in print and online that focuses on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. Nucleic Acid Therapeutics is the Official Journal of the Oligonucleotide Therapeutics Society. Complete tables of content and a free sample issue may be viewed on the Nucleic Acid Therapeutics website (http://www.liebertpub.com/nat).
About the Society
The Oligonucleotide Therapeutics Society (http://www.oligotherapeutics.org) is an open, nonprofit forum to foster academia and industry based research and development of oligonucleotide therapeutics. The society brings together the expertise from different angles of oligonucleotide research to create synergies and to bring the field of oligonucleotides to its full therapeutic potential.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Human Gene Therapy, Genetic Testing and Molecular Biomarkers, ASSAY and Drug Development Technologies, and DNA and Cell Biology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website (http://www.liebertpub.com).
Mary Ann Liebert, Inc. 140 Huguenot St., New Rochelle, NY 10801-5215
Phone: (914) 740-2100 (800) M-LIEBERT Fax: (914) 740-2101
http://www.liebertpub.com
New method to sensitize human ovarian cancer cells to a targeted cytotoxic drug
2013-05-30
ELSE PRESS RELEASES FROM THIS DATE:
Change, conflict cue memories of life's milestones: Study
2013-05-30
What will your kids remember about the life stories you tell them? New University of Alberta research shows that they're likely to be able to recall transitional moments you share with them, be it promotions or pets. The research offers strong evidence that societal values significantly affect how people think about and recall events in their lives—and how we potentially carry old values and beliefs forward in a new country.
Psychology researchers Connie Svob and Norman Brown conducted interviews with two groups of participants, split evenly between people born in Canada ...
Putting the brakes on distracted driving
2013-05-30
If you're still using your mobile phone behind the wheel, University of Alberta sociology researcher Abu Nurullah likely has your number.
More specifically, he can tell what statistical category you fall under. Using survey data from mid-2011—just months before Alberta's distracted-driving law went into effect—Nurullah and his colleagues determined several characteristics of people who appear to top the risk scale by using cellphones while driving. The data are useful for police who have to deal with unlawful drive-and-dialers, and for policy-makers seeking to change ...
Researchers shed new light on egg freezing success rates
2013-05-30
Researchers from New York Medical College and the University of California Davis have for the first time codified age-specific probabilities of live birth after in vitro fertilization (IVF) with frozen eggs. A team of researchers led by Kutluk Oktay, M.D., a New York Medical College physician/scientist who specializes in preserving the fertility of female cancer patients, conducted a meta-analysis of oocyte cryopreservation cycles using individualized patient data to report the probability of live-birth from IVF cycles.
The study, "Age-specific probability of live birth ...
Adult stem cells could hold key to curing Type 1 diabetes
2013-05-30
Millions of people with type 1 diabetes depend on daily insulin injections to survive. They would die without the shots because their immune system attacks the very insulin-producing cells it was designed to protect. Now, a University of Missouri scientist has discovered that this attack causes more damage than scientists realized. The revelation is leading to a potential cure that combines adult stem cells with a promising new drug.
The discovery is reported in the current online issue of Diabetes, the American Diabetes Association's flagship research publication. Habib ...
Science news from Harvard Stem Cell Institute
2013-05-30
May brought a major advancement in the science of aging when two Harvard Stem Cell Institute (HSCI) researchers announced their discovery of a protein circulating in the blood of mice and humans that shows potential to be a treatment for age-related heart failure. The protein, called GDF-11, reduced the size and thickness of the heart walls when injected into old mice.
There are hundreds of investigators in the HSCI network solving different problems related to cell biology and illness. This month, we feature recently published work by three laboratories on: a therapy ...
Higher-dose RT results in inferior survival in patients with stage III lung cancer
2013-05-30
In a randomized phase III clinical trial conducted by the Radiation Therapy Oncology Group (RTOG), high-dose (HD), compared with standard-dose (SD), radiotherapy (RT) with concurrent chemotherapy (CT) did not improve overall survival of patients with stage III non-small-cell lung cancer (NSCLC).
Philadelphia, PA—Of all the patients in the US with lung cancer, the country's leading cause of cancer death, 75 to 80 percent of them have NSCLC, with 30 to 40 percent of those being considered locally advanced (stage IIIA or IIIB). Although RT plus CT has been the standard ...
Stanford scientists develop high-efficiency zinc-air battery
2013-05-30
Stanford University scientists have developed an advanced zinc-air battery with higher catalytic activity and durability than similar batteries made with costly platinum and iridium catalysts. The results, published in the May 7 online edition of the journal Nature Communications, could lead to the development of a low-cost alternative to conventional lithium-ion batteries widely used today.
"There have been increasing demands for high-performance, inexpensive and safe batteries for portable electronics, electric vehicles and other energy storage applications," said Hongjie ...
Organic polymers show sunny potential
2013-05-30
A new version of solar cells created by laboratories at Rice and Pennsylvania State universities could open the door to research on a new class of solar energy devices.
The photovoltaic devices created in a project led by Rice chemical engineer Rafael Verduzco and Penn State chemical engineer Enrique Gomez are based on block copolymers, self-assembling organic materials that arrange themselves into distinct layers. They easily outperform other cells with polymer compounds as active elements.
The discovery is detailed online in the American Chemical Society journal Nano ...
Californians with 'medical home' more likely to get flu shots, preventive treatment
2013-05-30
Too many cooks may spoil a recipe, and too many doctors may give you the flu.
That's the takeaway from a new study by the UCLA Center for Health Policy Research that found that Californians who jump from provider to provider rather than seeing a regular doctor who coordinates their care may be less likely to get the kind of preventive treatment that protects against the flu and flare ups in their chronic conditions.
Specifically, the study used data from the 2009 California Health Interview Survey (CHIS) to estimate whether the approximately 4.76 million California ...
Task master: Categorizing rewards improves motivation
2013-05-30
What truly inspires individuals to perform at their very best? When it comes to motivating others and ourselves, it turns out offering rewards in defined categories, even when they are largely meaningless, can heighten motivation. According to recent research co-authored by Scott S. Wiltermuth, assistant professor of management and organization at USC's Marshall School of Business, even if the rewards are the similar – and the categories arbitrary – the very act of segmenting rewards motivates people to perform better and longer, even on menial tasks.
Wiltermuth's study, ...